[ad_1]
Most cancers medicine that work like heat-seeking missiles to ship chemical compounds on to tumors are having a little bit of a second.
Pharmaceutical firms, in want of belongings to counter flagging gross sales, are making these so-called antibody-drug conjugates the know-how of alternative in oncology dealmaking, as illustrated by the latest $10.1 billion acquisition of ImmunoGen by AbbVie.
If that pattern sounds vaguely acquainted, you might have most likely been following the pharma business for too lengthy. The sector has gone by means of waves of hype and funding over the previous a number of many years. This time, although, the hype is deserved.
[ad_2]
Source link
